Il tumôr de prostate al è il secont tumôr plui comun tai oms in dut il mont, cun cirche 1.276 milions di gnûfs câs segnalâts intal 2018, rapresentant il 7,1% di ducj i câs di tumôr tai oms.
Il tas di mortalitât pal tumôr de prostate al è ancje alt, cun cirche 37.005 muarts in dut il mont intal 2018.
Dut câs, il tas di mortalitât al varie une vore par ogni regjon, cun l'Afriche ocidentâl che e à il cuint plui alt risi di mortalitât par il cancar de prostate in dut il mont, e la Nigerie che e à la plui grande popolazion e economie in cheste regjon.
In Nagjerie, il cancar de prostate al è il cancar plui comun e plui mortâl pai oms, cun cirche 32,8 câs e 16,3 muarts ogni 100.000 oms.
Chest al è plui dal dople dal tas di mortalitât in Americhe dal Nord.
La diagnosi tardive de malatie, lis risorsis limitadis pal screening e la individuazion, e la diminuzion de documentazion e segnalazion dai câs a contribuissin al alt tas di mortalitât in Nigerie.
Intai Stâts Unîts, il cancar de prostate al è la seconde cause plui comun di muart par cancar tai oms, cun cirche 40.000 oms che a muerin par cheste malatie ogni an.
Il tas di mortalitât dal tumôr de prostate al è lât a mont dal inizi dai agns novante, ma al reste un probleme di salût impuartant.
In gjenerâl, il cancar de prostate al è une malatie mortâl, in particolâr tes regjons cun acès limitât a lis curis medichis e a lis risorsis pal screening.
Dut câs, une diagnosi e un tratament precoç a puedin miorâ in mût significatîf i risultâts e ridusi i tas di mortalitât.
Nakata S, Takahashi H, Ohtake N, Takei T, Yamanaka H: Trends and characteristics in prostate cancer mortality in Japan. Int J Urol. 2000, 7 (7): 254-7.
Pishgar F, Ebrahimi H, Saeedi Moghaddam S, Fitzmaurice C, Amini E: Global, Regional and National Burden of Prostate Cancer, 1990 to 2015: Results from the Global Burden of Disease Study 2015. J Urol. 2018, 199 (5): 1224-1232.
Cai Q, Chen Y, Zhang D, Pan J, Xie Z, Xu C, Li S, Zhang X, Gao Y, Hou J, Guo X, Zhou X, Zhang B, Ma F, Zhang W, Lin G, Xin Z, Niu Y, Wang Y: Estimates of over-time trends in incidence and mortality of prostate cancer from 1990 to 2030. Transl Androl Urol. 2020, 9 (2): 196-209.
Feletto E, Bang A, Cole-Clark D, Chalasani V, Rasiah K, Smith DP: An examination of prostate cancer trends in Australia, England, Canada and USA: Is the Australian death rate too high? World J Urol. 2015, 33 (11): 1677-87.
Taksler GB, Keating NL, Cutler DM: Explaining racial differences in prostate cancer mortality. Cancer. 2012, 118 (17): 4280-9.
['Disclaimer: medicâl']
['Chest sît web al è furnît dome par fins educatîfs e informatîfs e nol è une consulence o un servizi professionâl.']
['Lis informazions furnidis no àn di jessi dopradis par diagnosticâ o curâ un probleme di salût o une malatie, e chei che a vuelin une consulence mediche personâl a àn di consultâ un miedi autorizât.']
['Par plasê note che la rêt neuronâl che a gjenere lis rispuestis aes domandis, e je imprecise soredut cuant a si trate di contignûts numerics.']
['Cîr simpri la consulence dal to miedi o di un altri professionist in materie di salût a rivuart di une malatie. No sta mai dismenteâ la consulence di un miedi professionist o intardâti a cirîle par vie di alc che tu âs let su chest sît. Se tu pensis di vê une emergjence mediche, clame il 911 o va tal pronto socorso plui dongje.']
['Disclaimer: copyright']
['Il Digital Millennium Copyright Act dal 1998, 17 U.S.C. § 512 (il DMCA) al proviôt un ricors pai proprietaris di copyright che a crodin che il materiâl che al comparìs su Internet al violi i lôr dirits sot la leç sul copyright dai Stâts Unîts. ']
['Se tu crodis in buine fede che cualsisei contignût o materiâl disponibil in conession cul nestri sît o i nestris servizis al violi il tô copyright, tu (o il to agjent) tu puedis mandânus une notifiche domandant la rimozion dal contignût o dal materiâl, o il bloc dal acès. ']
['I avîs a àn di jessi mandâts par scrit vie e-mail (cjale la sezion "Contat" par vê l\'indiriç e-mail). ']
['La DMCA e domande che la tô notifiche di violazion dal copyright e vedi dentri chestis informazions: (1) descrizion dal lavôr protet dal copyright che al è ogjet de violazion rivendicade; (2) descrizion dal presunt contignût che al è une violazion e informazions suficientis par permeti di cjatâ il contignût; (3) informazions di contat, includût la tô direzion, numar di telefon e pueste eletroniche; (4) une declarazion di buine fede che il contignût al no è autorizât dal proprietari dal copyright, o dal so agjent, o par vie di une leç; ']
['5) une declarazion di bande tô, firmade sot pena di falsetât, che lis informazions inte notifiche a son veris e che tu âs la autoritât par fâ valê i dirits di autôr che a son stâts violats;']
['e (6) une firme fisiche o eletroniche dal titulâr dal copyright o di une persone autorizade a agjî par cont dal titulâr. ']
['Se no tu âs dutis lis informazions parsore, al podarès intardâ il tratament dal to reclam.']
['Contatât']
['Par plasê mandinus une e-mail cun ogni domande / sugjeriment.']
How deadly is prostate cancer?
Prostate cancer is the second most common cancer in men worldwide, with an estimated 1.276 million new cases reported in 2018, representing 7.1% of all cancer cases in men.
The mortality rate for prostate cancer is also high, with an estimated 37,005 deaths worldwide in 2018.
However, the mortality rate varies greatly by region, with Western Africa having the fifth-highest risk for prostate cancer mortality in the world, and Nigeria having the largest population and economy in this region.
In Nigeria, prostate cancer is both the most common and most deadly cancer for men, with an estimated 32.8 cases and 16.3 deaths per 100,000 men.
This is more than double the death rate in North America.
Late detection of the disease, limited resources for screening and detection, and decreased documentation and reporting of cases contribute to the high mortality rate in Nigeria.
In the United States, prostate cancer is the second most common cause of cancer death in men, with approximately 40,0000 men dying from the disease each year.
The prostate cancer death rate has been slowly decreasing since the early 1990s, but it remains a significant health concern.
Overall, prostate cancer is a deadly disease, particularly in regions with limited access to medical care and screening resources.
However, early detection and treatment can significantly improve outcomes and reduce mortality rates.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
['A rivuart']
['BioMedLib al dopre ordenadôrs automatics (algoritmi di aprendiment de machine) par gjenerâ cubiis di domandis e rispuestis.']
['Si scomence cun 35 milions di publicazions biomedichis di PubMed/Medline. e ancje lis pagjinis web di RefinedWeb.']
